Status:
COMPLETED
A Study Evaluating the Effects of Nebivolol on Blood Pressure in Hypertensive Patients
Lead Sponsor:
Mylan Bertek Pharmaceuticals
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the effects of various doses of nebivolol in patients with mild to moderate hypertension.
Detailed Description
This was a multi-center, randomized, double-blind, parallel group, placebo-controlled study of nebivolol over a range of doses in patients with mild to moderate hypertension. The study consisted of 2 ...
Eligibility Criteria
Inclusion
- An average sitting diastolic blood pressure of greater then or equal to 95 mmHg and less then or equal to 109 mmHg at baseline
Exclusion
- Recent myocardial infarction or stroke
- Secondary hypertension
- Contraindications to beta-blocker treatment or discontinuation of current antihypertensive therapy
- Pregnancy, nursing, or women of child-bearing potential not using appropriate contraception
Key Trial Info
Start Date :
September 1 2001
Trial Type :
INTERVENTIONAL
End Date :
March 1 2003
Estimated Enrollment :
825 Patients enrolled
Trial Details
Trial ID
NCT00200460
Start Date
September 1 2001
End Date
March 1 2003
Last Update
September 20 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mylan Pharmaceuticals Inc.
Morgantown, West Virginia, United States, 26505